Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL -0.95%40 Price-to-Tangible-Book is 5.15 as of Sep. 04, 2026. GuruFocus rates ASX:OSL with a GF Score™ of 40/100 and a GF Value™ of A$2.93 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 702 Medical Devices & Instruments companies, OncoSil Medical ranks worse than 74.22% on this metric.
The historical rank and industry rank for OncoSil Medical's Price-to-Tangible-Book or its related term are showing as below:
ASX:OSL'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.4 Med: 4.53 Max: 14.71
Current: 5.23
During the past 13 years, OncoSil Medical's highest Price to Tangible Book Ratio was 14.71. The lowest was 2.40. And the median was 4.53.
ASX:OSL's Price-to-Tangible-Book is ranked worse than 74.22% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 2.635
vs ASX:OSL: 5.23
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
OncoSil Medical Price-to-Tangible-Book Related Terms
OncoSil Medical Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSL vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, OncoSil Medical's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
OncoSil Medical (ASX:OSL) has a Price-to-Tangible-Book of 5.15 as of Sep. 04, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on OncoSil Medical and its competitors. According to the industry distribution chart, OncoSil Medical ranks #521 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 74.2%.
Is OncoSil Medical's Price-to-Tangible-Book too high?
OncoSil Medical's current Price-to-Tangible-Book is 5.15. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.64. OncoSil Medical's value of 5.15 is 95.4% above this industry median. Based on the distribution chart, OncoSil Medical ranks #521 out of 702 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, OncoSil Medical has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #521 out of 702 companies for Price-to-Tangible-Book. This places OncoSil Medical in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.64. OncoSil Medical's value of 5.15 is 95.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.64, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoSil Medical's current Price-to-Tangible-Book of 5.15 is 95.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current Price-to-Tangible-Book is 5.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.93, compared to a current price of A$1.05 — trading 64.3% below its estimated fair value. The current Price-to-Tangible-Book is 5.15 and 95.4% above the Medical Devices & Instruments industry median of 2.64. OncoSil Medical's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Price-to-Tangible-Book is 5.15 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.05 is trading 64.3% below its estimated GF Value™ of A$2.93.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Price-to-Tangible-Book: 5.15
GF Value™: A$2.93 vs. price of A$1.05 (64.3% below fair value)
Industry Position: 95.4% above the Medical Devices & Instruments median (#521 of 702)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
40GF Score
Get the complete analysis for ASX:OSL
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
